The SmartBio System for the Improved Preservation of Human Hematopoietic Stem Cells
用于改善人类造血干细胞保存的 SmartBio 系统
基本信息
- 批准号:9228432
- 负责人:
- 金额:$ 26.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-13 至 2018-07-14
- 项目状态:已结题
- 来源:
- 关键词:AblationAreaBathingBindingBiochemicalBiological AssayBiological PreservationBiological SciencesBiotechnologyBloodCell DeathCell SurvivalCell TherapyCell physiologyCellsCellular StressCellular biologyCharacteristicsChinese Hamster Ovary CellClinicalComputer softwareCouplingCryopreservationCryopreserved CellCryosurgeryDataDevelopmentDevice DesignsDevice or Instrument DevelopmentDevicesDocumentationEngineeringFDA approvedFreezingFutureGoalsHematopoietic stem cellsHomingHumanHuman CharacteristicsHuman ResourcesIndustryIndustry StandardInvestigationLettersMalignant NeoplasmsMalignant neoplasm of pancreasMarketingMedicalMedical DeviceMolecularMolecular AnalysisNatureOutcomePathway interactionsPerformancePhasePlayPositioning AttributeProceduresProcessProtocols documentationPublicationsReagentReproducibilityResearchSamplingSeriesStem cellsStressSystemTechnologyTestingTimeTissuesVial deviceWaterbasebiological researchbioprocessconditioningcost effectivecryobiologydesignexperienceimprovedimproved outcomein vivoinnovationinstrumentinterestknowledge basemedical schoolsnovelphase 1 studyproduct developmentprogramsprototyperesponsesuccesstargeted agenttechnology developmentuser-friendly
项目摘要
CPSI Biotech is a technology development company focused on the design of devices and
molecular modulation strategies in support of the biomedical and bioprocessing industries.
Through these efforts we have developed the PSN and SCN cryoablation systems for targeted
ablation of various cancers including pancreatic cancer. This unique medical device is now being
tested at Johns Hopkins School of Medicine. Given the favorable freezing and engineering
characteristics as well as performance profiles compared to comparable systems, CPSI has re-
tooled the PSN technology into a device, SmartFreeze, for the rapid and effective
cryopreservation of human cells and tissues beyond what is possible today. CPSI has also built a
prototype device, SmartThaw, designed for the enhanced, documentable and programmable dry
thawing of human cell products. This system is designed such that it has advantages over
traditional water bath thawing such as operator/software control design for unique thawing
programs. Furthermore, SmartThaw Gen7 demonstrates a 3 fold increase in post-thaw viability
of CHO cells compared to a standard water bath - a result that argues well for improved post-
thaw outcome when applied to stem cells. The SmartFreeze and SmartThaw devices
collectively make up the SmartBio platform. The unique features and documentable nature
uniquely position the SmartBio for inclusion for cell processing in FDA approved stem cell INDs.
Given the potential of SmartBio, under this project we will apply our extensive experience and
knowledge base on the cell biology, cryobiology and cryoengineering to develop a new class of
devices and strategies to enable the rapid and controlled freezing and thawing of human
hematopoietic stem cells (hHSCs). Phase 1 Specific Aims are the following: SA1 - Develop the
SmartThaw system for the improved thawing of hHSCs. SA2 - Couple the SmartThaw to the
SmartFreeze system developing cell specific freezing and thawing profiles that result in optimal
hHSC viability. SA3 - Test agents that target and ameliorate select cell stress pathways activated
in hHSCs following the freezing and thawing process; SA4 - Analyze functionality and
differentiation of hHSCs subsequent to the optimal freeze/thaw process. Phase 2 will focus on
device optimization, developing an hHSC-specific cryopreservation strategy for the SmartBio
system, performing homing studies and subsequent beta testing. The overall goal of the
SmartBio project is to improve hHSC post-thaw outcome by ≥50% over the current industry
standard. This proposal represents an integrative approach to product development coupling
engineering and life sciences that will yield the first tandem operator controlled and
documentable freezing and thawing systems specifically designed for the cell therapy arena.
CPSI Biotech是一家专注于设备设计的技术开发公司
分子调制策略支持生物医学和生物处理行业。
通过这些努力,我们开发了针对目标的PSN和SCN冷冻系统
包括胰腺癌在内的各种癌症的消融。现在,这种独特的医疗设备正在
在约翰·霍普金斯医学院测试。鉴于有利的冻结和工程
与可比系统相比,特征和性能概况,CPSI具有
将PSN技术的工具设置为SmartFreeze,以快速有效
对人类细胞和组织的冷冻保存超出了当今可能。 CPSI也建立了
原型设备,SmartThaw,专为增强,可记录和可编程的干燥设计
解冻人类细胞产品。该系统的设计使其具有优势
传统的水浴融化,例如用于独特解冻的操作员/软件控制设计
程序。此外,SmartThaw Gen7表现出3倍的速度生存能力增加
与标准水浴相比
将结果融化,当应用于干细胞。 SmartFreeze和SmartThaw设备
集体组成SmartBio平台。独特的功能和可记录的性质
独特地将SMARTBIO定位,以纳入FDA认可的干细胞IND中的细胞处理。
鉴于Smartbio的潜力,在此项目下,我们将运用我们的丰富经验,
细胞生物学,冷冻生物学和冷冻工程的知识基础,以开发新的类别
设备和策略,以使人类快速而受控的冰冻和融化
造血干细胞(HHSC)。第1阶段的特定目的如下:SA1-开发
改善HHSC的SmartThaw系统。 SA2-将SmartThaw搭配到
SmartFreeze系统开发细胞特定的冷冻和解冻轮廓,从而最佳
HHSC的生存能力。 SA3-靶向和改善精选细胞应力途径激活的测试剂
在冷冻和解冻过程之后的HHSC中; SA4-分析功能和
最佳冻结/解冻过程之后的HHSC的分化。第2阶段将重点关注
设备优化,为SmartBio制定HHSC特定的冷冻保存策略
系统,进行归巢研究以及随后的Beta测试。总体目标
SmartBio项目将与当前行业相比,将HHSC的HHSC后结果提高≥50%
标准。该建议代表了产品开发耦合的一种综合方法
工程和生命科学将产生第一个串联操作员的控制和
可记录的冻结和融化系统专为细胞疗法而设计。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John M BAUST其他文献
John M BAUST的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John M BAUST', 18)}}的其他基金
FrostBite-DMR - A new Drug-Free Approach for Treating Type 2 Diabetes Supplemental Request
FrostBite-DMR - 一种治疗 2 型糖尿病的新无药方法补充请求
- 批准号:
10748325 - 财政年份:2022
- 资助金额:
$ 26.4万 - 项目类别:
FrostBite-DMR - A New Drug-Free Approach for Treating Type 2 Diabetes
FrostBite-DMR——一种治疗 2 型糖尿病的无药物新方法
- 批准号:
10596881 - 财政年份:2022
- 资助金额:
$ 26.4万 - 项目类别:
The SmartBio System for the Improved Preservation of Human Hematopoietic Stem Cells
用于改善人类造血干细胞保存的 SmartBio 系统
- 批准号:
9925574 - 财政年份:2016
- 资助金额:
$ 26.4万 - 项目类别:
FrostBite - A Unique Catheter for Endoscopic Cryoablation
FrostBite - 用于内窥镜冷冻消融的独特导管
- 批准号:
8647726 - 财政年份:2014
- 资助金额:
$ 26.4万 - 项目类别:
FrostBite - A Unique Catheter for Endoscopic Cryoablation
FrostBite - 用于内镜冷冻消融的独特导管
- 批准号:
9984633 - 财政年份:2014
- 资助金额:
$ 26.4万 - 项目类别:
Enhanced Bioprocessing Strategies for Human Mesenchymal Stem Cells
人类间充质干细胞的增强生物加工策略
- 批准号:
8096921 - 财政年份:2011
- 资助金额:
$ 26.4万 - 项目类别:
Automated Device for High Throughput Cell Cryopreservation
高通量细胞冷冻保存自动化设备
- 批准号:
8059022 - 财政年份:2011
- 资助金额:
$ 26.4万 - 项目类别:
CellGuard - A Novel Approach for Protecting Cells During Bioprocessing
CellGuard - 生物加工过程中保护细胞的新方法
- 批准号:
7940083 - 财政年份:2009
- 资助金额:
$ 26.4万 - 项目类别:
CellGuard - A Novel Approach for Protecting Cells During Bioprocessing
CellGuard - 生物加工过程中保护细胞的新方法
- 批准号:
7671200 - 财政年份:2009
- 资助金额:
$ 26.4万 - 项目类别:
Development of an In Situ Anhydrobiotic Tissue Culture Process
原位脱水组织培养工艺的开发
- 批准号:
7481983 - 财政年份:2008
- 资助金额:
$ 26.4万 - 项目类别:
相似国自然基金
区域医疗一体化对基层医疗机构合理用药的影响及优化策略——基于创新扩散理论
- 批准号:72304011
- 批准年份:2023
- 资助金额:20 万元
- 项目类别:青年科学基金项目
面向有限监督信息的脑影像感兴趣区域分割及应用
- 批准号:62376123
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
壳聚糖-没食子酸“共价牵手”协同焦磷酸盐“区域保护”调控肌原纤维蛋白凝胶特性的分子机制研究
- 批准号:32302110
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
双区域自然对流耦合模型的高效数值方法研究
- 批准号:12361077
- 批准年份:2023
- 资助金额:28 万元
- 项目类别:地区科学基金项目
典型中小城市区域暴雨积水动态过程集合量化智能解析研究
- 批准号:52379008
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
A Nociceptin Central Amygdala to Hindbrain Circuit for the Control of Palatable Food Consumption
用于控制可口食物消耗的伤害感受肽中央杏仁核到后脑回路
- 批准号:
10413010 - 财政年份:2020
- 资助金额:
$ 26.4万 - 项目类别:
A Nociceptin Central Amygdala to Hindbrain Circuit for the Control of Palatable Food Consumption
用于控制可口食物消耗的伤害感受肽中央杏仁核到后脑回路
- 批准号:
10159256 - 财政年份:2020
- 资助金额:
$ 26.4万 - 项目类别:
Dissecting the role of vasopressin in regulating the critical period for social reward learning
剖析加压素在调节社会奖励学习关键期中的作用
- 批准号:
10316232 - 财政年份:2019
- 资助金额:
$ 26.4万 - 项目类别:
Dissecting the role of vasopressin in regulating the critical period for social reward learning
剖析加压素在调节社会奖励学习关键期中的作用
- 批准号:
10531267 - 财政年份:2019
- 资助金额:
$ 26.4万 - 项目类别:
Dissecting the role of vasopressin in regulating the critical period for social reward learning
剖析加压素在调节社会奖励学习关键期中的作用
- 批准号:
9885422 - 财政年份:2019
- 资助金额:
$ 26.4万 - 项目类别: